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ABSTRACT
This study tested the hypothesis that endogenous bradykinin
contributes to the effects of angiotensin AT1 receptor blockade
in humans. The effect of the bradykinin B2 receptor antagonist
D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg (HOE-140) (18
g/kg/h i.v. for 6 h) on hemodynamic and endocrine responses
to acute and chronic (1-month) treatment with valsartan (160
mg/day) was determined in 13 normotensive and 12 hyperten-
sive salt-deplete subjects. Acute valsartan increased plasma
renin activity (PRA) from 5.3  9.9 to 15.6  19.8 ng of angio-
tensin (Ang) I/ml/h (P  0.001) and decreased aldosterone from
18.3  10.5 to 12.0  9.6 ng/dl (P  0.001). Chronic valsartan
significantly increased baseline PRA (10.5  15.5 ng of Ang
I/ml/h; P  0.004) but did not affect baseline angiotensin-
converting enzyme activity or aldosterone. HOE-140 tended to
increase the PRA response to valsartan, and it attenuated the
decrease in aldosterone following chronic valsartan (P  0.03).
Acute valsartan decreased mean arterial pressure 12.7  6.9%
(from 100.2  8.4 to 87.5  9.8 mm Hg in hypertensives and
from 82.4  8.6 to 70.3  8.4 mm Hg in normotensives).
HOE-140 did not affect the blood pressure response to either
acute (effect of valsartan, P  0.001; effect of HOE-140, P 
0.98) or chronic (valsartan, P  0.01; HOE-140, P  0.84)
valsartan. Plasma cGMP was increased significantly during
chronic valsartan (P  0.048) through a bradykinin receptor-
independent mechanism (effect of HOE-140, P  0.13). Both
acute (P  0.001) and chronic (P  0.001) valsartan increased
heart rate. HOE-140 augmented the heart rate response to
chronic valsartan (P  0.04). These data suggest that endog-
enous bradykinin does not contribute significantly to the blood
pressure-lowering effect of valsartan through its B2 receptor.
The availability of the specific bradykinin B2 receptor antag-
onist D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg (HOE-140)
as well as the combined B1 and B2 antagonist D-Arg-Arg-Pro-
Hyp-Gly-Thi-Ser-D-Igl-Oic-Arg (B9340) has allowed investiga-
tors to determine the contribution of endogenous bradykinin
to the effects of angiotensin-converting enzyme (ACE) inhib-
itors in animals and humans. For example, Gainer et al.
(1998) demonstrated that coadministration of HOE-140 at-
tenuated the hemodynamic and endocrine effects of acute
ACE inhibition in normotensive subjects and hypertensive
subjects of both African-American and Caucasian race. Like-
wise, HOE-140 attenuated the acute hypotensive response to
perindoprilat in normotensive subjects (Squire et al., 2000).
In congestive heart failure patients treated chronically with
ACE inhibitor, combined B1 and B2 inhibition, but not B2
inhibition alone, caused vasoconstriction (Davie et al., 1999;
Witherow et al., 2001).
Whether bradykinin contributes to the blood pressure-low-
ering effect of AT1 receptor blockade remains to be deter-
mined. Unlike ACE inhibition, acute AT1 receptor blockade
does not potentiate the vasodilator effects of exogenous bra-
dykinin in the human forearm vasculature (Cockcroft et al.,
1993). However, this does not exclude the possibility that
endogenous bradykinin contributes to the effects of either
acute or chronic administration of an AT1 receptor antago-
nist. Indeed, studies in vitro and in animals suggest a mech-
anism whereby bradykinin may contribute to the effects of
AT1 receptor blockade. During AT1 receptor blockade, excess
angiotensin II (Ang II) increases bradykinin and subse-
quently NO through an AT2 receptor-dependent mechanism
in the aorta (Gohlke et al., 1998; Tsutsumi et al., 1999) as
well as the kidney (Siragy and Carey, 1997). Moreover, the
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absence of AT2 receptors in genetically modified mice has
been associated with an increase in ACE activity and de-
creased sensitivity to exogenous bradykinin infusion (Hunley
et al., 2000).
The contribution of endogenous bradykinin to the effects of
AT1 receptor blockade in humans is not well defined. Two
groups have reported no effect of HOE-140 or B9340 on
vasodilation in congestive heart failure patients treated
chronically with the AT1 receptor antagonist losartan (Davie
et al., 1999; Cruden et al., 2004). In contrast, Hornig et al.
(2003) observed that HOE-140 attenuated the effect of can-
desartan on flow-mediated vasodilation in patients with cor-
onary artery disease. Campbell et al. (2005) reported that
losartan, but not eprosartan, increased circulating bradyki-
nin concentrations in hypertensive subjects. In the current
study, we tested the hypothesis that bradykinin contributes
to the blood pressure-lowering effect of either acute or
chronic (1-month) administration of the AT1 receptor antag-
onist valsartan in salt-deplete normotensive and hyperten-
sive subjects.
Materials and Methods
Overall Study Protocol. The single-blind, crossover design pro-
tocol was approved by the Vanderbilt Institutional Review Board,
and all subjects gave written informed consent. The study was con-
ducted in accordance with the Declaration of Helsinki. Following
screening history and physical examination, subjects were given
placebo for 2 to 4 weeks. Any antihypertensive medications were
discontinued or withdrawn during this period such that all hyper-
tensive subjects were off -blockers, ACE inhibitors, or AT1 receptor
blockers for at least 3 weeks, and they were off all other medications
for at least 1 week before the first infusion study day. During the last
week of placebo run-in, subjects were provided a low (10 mmol/day)
sodium diet for 8 days. On the 5th and 7th days of diet, subjects
collected their urine for 24 h for measurement of sodium excretion.
On the 6th and 8th days of diet, subjects presented to the Vanderbilt
General Clinical Research Center (Nashville, TN) for oral adminis-
tration of valsartan and intravenous administration of either HOE-
140 or vehicle. Following the second infusion day, subjects were
provided valsartan at 160 mg/day for 4 weeks. During the last week
of valsartan administration, the low sodium diet, 24-h urine collec-
tions, and HOE-140 and vehicle infusions were repeated.
To control for the effect of time and HOE-140 alone on the study
variables, seven subjects (five male, two female; five white, two black
American; four hypertensive, three normotensive) completed a sec-
ond protocol, identical to the first except that subjects were given
placebo rather than valsartan during HOE-140 and vehicle infusion
days, and the chronic phase was omitted.
HOE-140/Vehicle Infusion Protocol. Subjects reported to the
Vanderbilt General Clinical Research Center in the fasting state at
7:00 AM. An intravenous catheter was placed in the antecubital vein
of each arm, one catheter for drawing blood and the other catheter
for administering drugs. Thirty minutes later subjects were given a
loading dose of p-aminohippurate (PAH; 8 mg/kg) followed by a
constant infusion of 12 mg/min for measurement of renal blood flow.
One hour after PAH was started, subjects were given valsartan 160
mg (time 0), and HOE-140 or vehicle was infused. HOE-140 was
given as a loading dose of 22 g/kg, followed by a continuous infusion
of 18 g/kg/h for 6 h, a dose that has been shown previously to
attenuate the vasodilator effect of bradykinin (Cockcroft et al., 1994).
In a pilot study, this dose of HOE-140 was confirmed to block the
potentiating effect of enalaprilat on bradykinin-induced vasodilation
in the forearm. The duration of HOE-140 infusion was chosen to
continue until the peak hypotensive effect of valsartan had been
achieved. Blood pressure and heart rate were monitored every 5 min
throughout the study using an automated blood pressure cuff, and
rates were averaged over 1-h intervals.
Blood for measurement of plasma renin activity (PRA), ACE ac-
tivity, Ang II, aldosterone, cGMP, NO metabolites, bradykinin and
its metabolite BK1-5, and PAH was obtained at 0, 2, 4, 6, and 8 h
following administration of valsartan. All samples from at least the
first five subjects were assayed to establish the time course for each
variable. Thereafter, only the samples from time 0 (designated base-
line in the tables) and from the time associated with the maximum
effect following valsartan (post) were assayed. For Ang II, the peak
effect occurred at 2 h following valsartan. For all other variables, this
was at 6 h following losartan. Urine collected 2 h before and from 6
to 8 h following valsartan was assayed for NO metabolites and
BK1-5.
Laboratory Analysis. All blood samples were centrifuged for 20
min immediately following blood drawing, and the plasma or serum
was stored at 80°C until the time of analysis. Blood for PRA and
aldosterone was drawn in chilled tubes containing EDTA. PRA was
measured by radioimmunoassay for Ang I formation at pH 7.4 and
37°C (Workman et al., 1979). Aldosterone was measured using a
commercially available radioimmunoassay (Diagnostic Products, Los
Angeles, CA). Blood for Ang II determination was collected in chilled
tubes containing a cocktail of protease inhibitors, and Ang II mea-
surements were made by radioimmunoassay, as described previously
(Kohara et al., 1991; Senananyake et al., 1994). Serum ACE activity
was determined by a three-step colorimetric assay in which ACE
hydrolyzes the substrate p-hydroxybenzoyl-glycyl-L-histidyl-L-
leucine, and subsequent reactions lead to the formation of quinone-
imine dye, which was measured spectrophotometrically (Fujirebio
America Inc., Fairfield, NJ). Bradykinin was measured by enzyme
immunoassay (Peninsula Laboratories, Belmont, CA and Bachem
California, Torrance, CA), and BK1-5 was measured using liquid
chromatography-mass spectroscopy, as described previously (Mur-
phey et al., 2001). PAH was measured in 18 subjects as described
previously (Shoback et al., 1983). Renal vascular resistance (RVR)
was calculated as mean arterial pressure (MAP)/renal blood flow.
Venous plasma and urine concentrations of NO metabolites were
measured using a modified Griess reaction (Actif Motif, Carlsbad,
CA). cGMP was measured by enzyme-linked immunosorbent assay,
using a commercially available kit (Amersham Biosciences, Piscat-
away, NJ).
Statistics. Data are presented as means  S.D. in the text and
tables and as means  S.E.M. in the figures. The effect of treatment
on blood pressure and heart rate was assessed using repeated mea-
sures analysis of variance in which the within-subject variables were
acute or chronic valsartan therapy, the presence or absence of HOE-
140, and time. Missing data (e.g., 27 of 900 MAP time points) were
replaced by series means. For neurohumoral variables, changes pre-
and postvalsartan during acute and chronic valsartan or in the
presence or absence of HOE-140 were compared using a paired
Student’s t test or Wilcoxon signed rank test, as appropriate. A
two-sided P value  0.05 was considered significant.
Results
Thirteen normotensive and 12 hypertensive subjects com-
pleted the full study. Their baseline characteristics are
shown in Table 1. Hypertensive subjects were heavier and
had a higher MAP compared with normotensive subjects. An
additional subject (a 39-year-old white female, not included
in the data analysis) was excluded after her first study day
(valsartan  HOE-140), after she developed pulmonary em-
boli, and it was discovered that she had begun taking an oral
contraceptive and she was heterozygous for the Factor V
Leiden mutation. The data and safety monitoring committee
of the study concluded that the adverse event was probably
not related to study drug.
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Table 2 provides baseline hemodynamic and renal data in
the normotensive and hypertensive subjects on each of the
four study days. Baseline parameters were similar on the
vehicle and HOE-140 study days during both acute and
chronic valsartan. MAP was significantly higher in the hy-
pertensive subjects than in the normotensive subjects on all
4 study days. In both normotensive and hypertensive sub-
jects, chronic valsartan decreased baseline MAP. Baseline
RVR was significantly higher in hypertensive subjects than
in normotensive subjects before treatment with acute valsar-
tan but not during chronic valsartan. Chronic valsartan ther-
apy significantly decreased baseline RVR in hypertensive
subjects but not in normotensive subjects. There was no
difference in baseline heart rate or urine sodium excretion
between normotensive and hypertensive subjects or between
acute and chronic valsartan study days.
Figure 1 shows the effect of treatment on MAP. Although
MAP was higher in the hypertensive subjects studied, the
change in MAP normalized as a percentage of baseline MAP
was statistically similar in the normotensive and hyperten-
sive subjects studied; therefore, the data for the two groups
are presented together. Neither placebo nor HOE-140 alone
significantly affected MAP. Acute administration of valsar-
tan lowered MAP 12.7  6.9% (P  0.001, from 82.4  8.6 to
70.3  8.4 mm Hg in normotensive subjects and from 100.2 
8.4 to 87.5  9.8 mm Hg in hypertensive subjects), with a
peak effect at 6 h. Following chronic valsartan, the relative
change in MAP was less than following acute dosing (P 
0.01 for effect of valsartan, P  0.001 versus acute valsar-
tan), but the baseline MAP was lower. Bradykinin receptor
blockade did not affect the blood pressure response to val-
sartan.
Heart rate increased significantly following both acute
(P  0.001) and chronic (P  0.001) administration of val-
sartan but not following placebo or placebo  HOE-140 (Fig.
2). After adjustment for age, bradykinin receptor blockade
significantly enhanced the heart rate response to chronic
valsartan (P  0.04) but not to acute valsartan (P  0.38). In
subgroup analysis, the effect of HOE-140 on the heart rate
response to chronic valsartan was seen in hypertensive sub-
jects (P  0.04) but not in normotensive subjects (P  0.16).
Acute valsartan decreased RVR from 0.147  0.037 to
0.115  0.044 mm Hg/[ml/min/1.73 M2] (P  0.001) at a nadir
of 6 h in the normotensive and hypertensive subjects com-
bined, from 0.129  0.026 to 0.094  0.037 mm Hg/[ml/min/
1.73 M2] (P  0.01) in the normotensive subjects, and from
0.162  0.039 to 0.130  0.042 mm Hg/[ml/min/1.73 M2] (P 
0.01) in hypertensive subjects. During chronic valsartan,
RVR decreased from 0.124  0.028 to 0.104  0.035 mm
Hg/[ml/min/1.73 M2] (P  0.001) 6 h following drug dosing in
the combined groups, from 0.115  0.021 to 0.094  0.031
mm Hg/[ml/min/1.73 M2] (P  0.03) in normotensive sub-
jects, and from 0.132  0.032 to 0.113  0.037 mm Hg/[ml/
min/1.73 M2] (P  0.06) in hypertensive subjects. There was
no effect of bradykinin receptor blockade on the change in
RVR following acute (P  0.23) or chronic (P  0.85) valsar-
tan either in all subjects combined or within hypertensive or
normotensive subjects.
Table 3 shows the effect of acute and chronic valsartan on
the renin-angiotensin-aldosterone and kallikrein-kinin sys-
tems in the presence and absence of the bradykinin receptor
TABLE 1
Subject characteristics
Characteristic Normotensive(n  13)
Hypertensive
(n  12) P Value
Gender (male/female) 6:7 7:5 N.S.
Race (white/black) 9:4 5:7 N.S.
Age (years) 42.9  9.8 46.3  7.5 N.S.
Body mass index (kg/M2) 25.1  2.3 27.8  1.8 0.003
MAP (mm Hg) 83.3  8.3 99.2  6.9 0.001
Heart rate (bpm) 63.6  9.6 67.9  7.6 N.S.
N.S., not significant.
TABLE 2
Baseline hemodynamic and renal data by study day
Parameter
Acute Chronic
Valsartan Valsartan  HOE-140 Valsartan Valsartan  HOE-140
MAP (mm Hg)
Normotensive 82.4  8.6 84.1  9.4 75.5  7.4* 75.1  8.5*
Hypertensive 100.2  8.4† 98.2  7.6† 91.1  8.8*† 92.0  7.4*†
Heart rate (bpm)
Normotensive 63.0  10.5 64.1  8.9 62.6  8.0 63.8  9.6
Hypertensive 68.1  6.9 67.6  8.8 67.5  10.0 68.9  12.6
RVR (mm Hg/ml/min/1.73 M2)
Normotensive 0.129  0.026 0.122  0.020 0.115  0.021 0.109  0.022
Hypertensive 0.162  0.039‡ 0.166  0.036§ 0.132  0.032 0.135  0.036*
24-h Urine sodium (mmol)
Normotensive 18.4  9.8 17.6  14.4 21.3  15.2 25.6  22.2
Hypertensive 39.8  55.6 28.2  11.9 33.8  16.2 30.7  18.8
* P  0.05 versus acute.
† P  0.001 versus normotensive.
‡ P  0.05 versus normotensive.
§ P  0.005 versus normotensive.
Fig. 1. Left, change in MAP in response to an acute dose of 160 mg of
valsartan (circles) or placebo (squares) in the presence (filled) and ab-
sence (open) of HOE-140. P  0.001 for effect of valsartan Right, change
in MAP in response to 160 mg of valsartan in the presence or absence of
HOE-140 after chronic (1-month) dosing. P  0.01 for effect of valsartan;
P  0.001 versus acute valsartan.
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antagonist HOE-140. Table 4 provides control data for the
effect of placebo in the presence or absence of HOE-140. All
baseline parameters were similar on vehicle and HOE-140
study days, during either acute or chronic valsartan admin-
istration. ACE activity decreased slightly after administra-
tion of acute and chronic valsartan as well as following pla-
cebo; the magnitude of this change was similar in the
presence and absence of HOE-140. There was no effect of
chronic valsartan therapy on baseline ACE activity. Acute
valsartan administration significantly increased PRA com-
pared with either baseline or placebo. Chronic valsartan
therapy significantly increased baseline morning PRA, and
there was a further increase following valsartan dosing.
HOE-140 tended to accentuate the change in PRA following
valsartan (P  0.05). Ang II concentrations increased follow-
ing either acute or chronic valsartan administration but not
following placebo. Mean baseline Ang II concentrations were
significantly higher during chronic valsartan compared with
before acute valsartan (P  0.02). There was no effect of
HOE-140 on Ang II concentrations. Serum aldosterone con-
centrations decreased after dosing of acute or chronic valsar-
tan as well as after placebo. HOE-140 did not affect the
decrease in aldosterone following acute valsartan. Chronic
valsartan therapy tended to decrease baseline morning aldo-
sterone concentration (P  0.07). Bradykinin receptor antag-
onism blunted the decrease in aldosterone following chronic
valsartan (P  0.03).
There was no effect of acute or chronic valsartan or of
bradykinin receptor blockade on plasma bradykinin, BK1-5
concentrations, or the ratio of BK1-5 to bradykinin, or on
urine BK1-5 concentrations (data not shown). There was no
effect of placebo or HOE-140 alone on plasma cGMP. Plasma
cGMP decreased following both acute and chronic valsartan
administration (P  0.04 for effect of time). Overall, however,
plasma cGMP concentrations were significantly higher (P 
0.048) during chronic valsartan administration than during
acute valsartan administration. There was no difference in
cGMP concentrations between normotensive and hyperten-
sive subjects (P  0.85). There was no effect of bradykinin
receptor blockade on plasma cGMP during valsartan (P 
0.13). There was no effect of placebo, valsartan or bradykinin
receptor antagonism on plasma NO metabolites (data not
shown) or on urinary excretion of NO metabolites.
Discussion
This study tested the hypothesis that endogenous brady-
kinin contributes to the blood pressure-lowering effect of
either acute or chronic AT1 receptor blockade in salt-deplete
normotensive and hypertensive subjects. Angiotensin AT1
Fig. 2. Left, effect of an acute dose of 160 mg of valsartan (circles) or
placebo (squares) on heart rate in the presence (filled) or absence (open)
of HOE-140. P  0.001 for effect of valsartan. Right, effect of 160 mg of
valsartan in the presence or absence of HOE-140 after chronic (1-month)
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receptor blockade with valsartan did not affect baseline se-
rum ACE activity or the ratio of BK1-5/bradykinin, a mea-
sure of vascular ACE activity (Murphey et al., 2000). Like-
wise, HOE-140, given at a dose that attenuated the response
to exogenous bradykinin, did not attenuate the hypotensive
effect of valsartan. Together, these data indicate that AT1
receptor blockade lowers blood pressure through a bradyki-
nin B2 receptor-independent mechanism in salt-deplete indi-
viduals.
Studies in animal models indicate that, during AT1 recep-
tor blockade, Ang II increases vascular and renal cGMP via
AT2 receptor-mediated stimulation of bradykinin and nitric
oxide synthesis (Siragy and Carey, 1997; Gohlke et al., 1998;
Tsutsumi et al., 1999). This effect is more pronounced follow-
ing administration of valsartan, the AT1 receptor antagonist
used in this study, than following losartan (Siragy et al.,
2002). We found no effect of valsartan on urinary NO metab-
olite excretion in salt-deplete normotensive and hypertensive
subjects. However, chronic valsartan administration in-
creased circulating cGMP, and this effect was not attenuated
by bradykinin receptor antagonism. This is consistent with
data from Siragy and co-workers indicating that AT1 receptor
blockade can increase NO and cGMP production through an
AT2 receptor-dependent, B2 receptor-independent mecha-
nism under conditions of salt depletion (Abadir et al., 2003).
Previous studies report no effect of HOE-140 on heart rate
during acute ACE inhibition (Gainer et al., 1998; Squire et
al., 2000). Likewise, bradykinin receptor blockade did not
affect heart rate response to acute valsartan administration.
In contrast, HOE-140 enhanced the heart rate response to
valsartan following 1-month administration. Whereas brady-
kinin can increase heart rate through sympathoexcitatory
reflexes (Veelken et al., 1996) and through local effects on
norepinephrine release (Seyedi et al., 1997), bradykinin in-
duces a negative chronotropic effect through intrinsic cardiac
cholinergic neurons in the isolated rabbit heart (Izrailtyan
and Kresh, 1997) and via a direct effect on the sinus node in
ganglion-blocked dogs (Ribuot et al., 1993). Bradykinin also
causes bradycardia in anesthetized cats (Prostran et al.,
1991) and in hypovolemic rats (Gardiner and Bennett, 1992).
Genetic disruption of the B2 receptor has been reported to
increase heart rate in some studies (Emanueli et al., 1999)
but not in others (Milia et al., 2001). As in the present study
in humans, HOE-140 has been reported to increase heart
rate in both a rat model (Carini et al., 2002) and in captopril-
treated, sodium-depleted marmosets (Panzenbeck et al.,
1995). Further studies are needed to address the mechanism
through which endogenous bradykinin modulates the heart
rate response to vasodilation during chronic AT1 receptor
blockade.
We found no effect of acute or chronic administration of
valsartan on circulating concentrations of bradykinin,
BK1-5, or the ratio of BK1-5 to bradykinin. This finding
conflicts with the data of Campbell et al. (2005) who reported
that losartan increased bradykinin concentrations in hyper-
tensive subjects (Campbell et al., 2005). In contrast, the
investigators did not find a significant effect of eprosartan on
bradykinin concentrations at a dose that did increase plasma
concentrations of Ang I, Ang II, and Ang-(2-8), raising the
possibility that the effect of losartan on kinin concentrations
was not a class effect. AT1 receptor antagonists differ in their
AT1 binding properties and in their AT1 receptor-indepen-
dent properties (de Gasparo, 2004). For example, among val-
sartan and the two AT1 receptor antagonists studied by
Campbell et al. (2005), eprosartan and valsartan have higher
affinity for the AT1 receptor than does losartan. Losartan and
eprosartan exhibit surmountable antagonism, whereas val-
sartan exhibits mixed surmountable-insurmountable antag-
onism. Losartan inhibits platelet aggregation through an
AT1-independent mechanism, whereas valsartan does not.
Despite these differences, both losartan and valsartan have
been shown to decrease mortality in individuals with heart
disease (Cohn et al., 2001; Dahlof et al., 2002).
The acute administration of valsartan significantly in-
creased PRA and Ang II, and basal PRA and Ang II were
higher during chronic valsartan, consistent with inhibition of
the short negative feedback loop on renin and Ang II produc-
tion (Kurtz and Wagner, 1999). In contrast to a previous
study of the effect of bradykinin receptor antagonism on
responses to ACE inhibition (Gainer et al., 1998), HOE-140
did not attenuate the renin response to valsartan. However,
bradykinin receptor antagonism blunted the decrease in al-
dosterone following chronic valsartan. This is consistent with
data indicating that administration of a kallikrein inhibitor
to prevent the formation of endogenous bradykinin enhances
adrenocorticotropic hormone-stimulated aldosterone synthe-
sis (Rebuffat et al., 2000).
A few limitations of the current study warrant mention.
First, although we administered HOE-140 through the pe-
riod of peak response to acute and chronic administration of
valsartan, the peptide nature and expense of the antagonist
did not permit longer administration. The lack of availability
of an orally active bradykinin receptor antagonist for admin-
istration to humans precludes studying the effect of concur-
TABLE 4
Effects of placebo and HOE-140 on parameters of the renin-angiotensin-aldosterone and kallikrein-kinin systems
Parameter
Placebo Placebo  HOE-140
Baseline Post- Baseline Post-
ACE (IU/ml) 36.8  17.4 22.6  23.2* 25.7  17.0 26.5  18.9
PRA (ng Ang I/ml/h) 2.1  1.9 1.7  1.3† 1.4  1.1 1.5  1.5‡
Ang II (pg/ml) 70.1  46.7 70.4  50.9† 64.0  56.9 70.5  41.6†
Aldosterone (ng/dl) 18.0  10.4 12.1  4.8 13.5  4.9 9.8  5.5*
Bradykinin (fmol/ml) 6.6  4.0 2.6  1.2 3.3  3.9 7.2  8.1
Bradykinin 1-5 (fmol/ml) 17.3  29.2 17.3  23.8 4.1  2.4 7.5  9.1
Plasma cGMP (nM) 14.8  4.0 14.7  4.0 16.8  4.6 17.2  6.7
Urine nitrate  nitrite (mol/g Cr) 253.3  116.7 383.8  178.2 310.2  179.8 292.3  130.6
* P  0.05 versus baseline.
† P  0.05 versus following valsartan.
‡ P  0.005 versus following valsartan.
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rent chronic bradykinin receptor antagonism on the response
to chronic valsartan. We studied subjects during salt deple-
tion because we had previously demonstrated that endoge-
nous bradykinin contributes to the blood pressure-lowering
effect of ACE inhibition under these conditions (Gainer et al.,
1998); thus, we cannot exclude the possibility that endoge-
nous bradykinin contributes to the hypotensive effect of AT1
receptor blockade in salt-replete individuals.
In addition, in a study in patients with congestive heart
failure, combined B1 and B2 receptor blockade, but not B2
receptor blockade alone, attenuated the hypotensive effects
of ACE inhibition (Witherow et al., 2001). Likewise, Gavras
and coworkers have reported that combined B1 and B2 recep-
tor antagonism increased blood pressure in rats, whereas B2
receptor antagonism alone did not (Duka et al., 2006). How-
ever, although it is possible that endogenous kinins could
contribute to the hypotensive effects of valsartan through a
B1 receptor-dependent mechanism, the B2-specific antago-
nist HOE-140 attenuates exogenous bradykinin-stimulated
vasodilation at the dose given. Likewise the B1 receptor ag-
onist Lys-des-Arg9-bradykinin does not cause vasodilation
when infused into the brachial artery of ACE inhibitor-
treated subjects (Cruden et al., 2005). Moreover, the results
of the present study are in agreement with data of Cruden et
al. (2004) who reported no effect of the combined B1 and B2
receptor antagonist B9340 on the hypotensive response to
AT1 receptor blockade with losartan in patients with conges-
tive heart failure.
In conclusion, ACE inhibitors and AT1 receptor blockers
have become the mainstay of treatment for the prevention of
morbidity and mortality in patients with congestive heart
failure, at risk for coronary artery disease, and with nephrop-
athy. Previous studies indicate that endogenous bradykinin
contributes to the hemodynamic effects of ACE inhibitors
(Gainer et al., 1998; Witherow et al., 2001). Whereas early
studies indicated that acute AT1 receptor blockade did not
potentiate the vasodilator response to exogenous bradykinin
(Cockcroft et al., 1993), a more recent study suggested that
AT1 receptor blockade may enhance endothelial function
through endogenous bradykinin (Hornig et al., 2003). At the
same time, studies in animals provided a plausible mecha-
nism whereby endogenous bradykinin could contribute to the
hypotensive effects of chronic AT1 receptor blockade (Siragy
and Carey, 1997; Gohlke et al., 1998). The present study does
not support the hypothesis that endogenous bradykinin con-
tributes significantly to the hypotensive effect of oral AT1
receptor blockade in humans via its B2 receptor.
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